Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors.

Eder M, Pavan S, Bauder-Wüst U, van Rietschoten K, Baranski AC, Harrison H, Campbell S, Stace CL, Walker EH, Chen L, Bennett G, Mudd G, Schierbaum U, Leotta K, Haberkorn U, Kopka K, Teufel DP.

Cancer Res. 2019 Feb 15;79(4):841-852. doi: 10.1158/0008-5472.CAN-18-0238. Epub 2019 Jan 3.

PMID:
30606721
2.

Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing "the lead" into PSMA-targeted alpha therapy?

Dos Santos JC, Schäfer M, Bauder-Wüst U, Lehnert W, Leotta K, Morgenstern A, Kopka K, Haberkorn U, Mier W, Kratochwil C.

Eur J Nucl Med Mol Imaging. 2019 Jan 3. doi: 10.1007/s00259-018-4220-z. [Epub ahead of print]

PMID:
30603987
3.

68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis.

Sachpekidis C, Pan L, Hadaschik BA, Kopka K, Haberkorn U, Dimitrakopoulou-Strauss A.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):351-359. eCollection 2018.

4.

Imaging and radiotherapy for recurrent prostate cancer: An evolutionary partnership.

Murray JR, Kopka K, Afshar-Oromieh A.

Radiother Oncol. 2018 Nov;129(2):387-388. doi: 10.1016/j.radonc.2018.09.016. Epub 2018 Oct 15. No abstract available.

PMID:
30336957
5.

Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid.

Hugenberg V, Behrends M, Wagner S, Hermann S, Schäfers M, Kolb HC, Szardenings K, Walsh JC, Gomez LF, Kopka K, Haufe G.

EJNMMI Radiopharm Chem. 2018 Jul 27;3:10. doi: 10.1186/s41181-018-0045-0. eCollection 2018 Dec.

6.

Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.

Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, Neels O, Schiller K, Amaral H, Weber WA, Haberkorn U, Schwaiger M, Kratochwil C, Choyke P, Kramer V, Kopka K, Eiber M.

J Nucl Med. 2019 Mar;60(3):362-368. doi: 10.2967/jnumed.118.212233. Epub 2018 Jul 24.

PMID:
30042163
7.

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2045-2054. doi: 10.1007/s00259-018-4079-z. Epub 2018 Jul 7.

8.

68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients.

Koerber SA, Will L, Kratochwil C, Haefner MF, Rathke H, Kremer C, Merkle J, Herfarth K, Kopka K, Choyke PL, Holland-Letz T, Haberkorn U, Debus J, Giesel FL.

J Nucl Med. 2018 Jul 5. pii: jnumed.118.211086. doi: 10.2967/jnumed.118.211086. [Epub ahead of print]

PMID:
29976697
9.

Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging.

Sachpekidis C, Goldschmidt H, Kopka K, Kopp-Schneider A, Dimitrakopoulou-Strauss A.

EJNMMI Res. 2018 Apr 10;8(1):28. doi: 10.1186/s13550-018-0383-7.

10.

Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT.

Afshar-Oromieh A, Sattler LP, Steiger K, Holland-Letz T, da Cunha ML, Mier W, Neels O, Kopka K, Weichert W, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1179-1187. doi: 10.1007/s00259-018-3965-8. Epub 2018 Mar 1.

PMID:
29497802
11.

Monomeric and Dimeric 68Ga-Labeled Bombesin Analogues for Positron Emission Tomography (PET) Imaging of Tumors Expressing Gastrin-Releasing Peptide Receptors (GRPrs).

Liolios C, Buchmuller B, Bauder-Wüst U, Schäfer M, Leotta K, Haberkorn U, Eder M, Kopka K.

J Med Chem. 2018 Mar 8;61(5):2062-2074. doi: 10.1021/acs.jmedchem.7b01856. Epub 2018 Feb 22.

PMID:
29432691
12.

Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT.

Giesel FL, Will L, Kesch C, Freitag M, Kremer C, Merkle J, Neels OC, Cardinale J, Hadaschik B, Hohenfellner M, Kopka K, Haberkorn U, Kratochwil C.

J Nucl Med. 2018 Apr;59(4):632-635. doi: 10.2967/jnumed.117.196329. Epub 2018 Feb 1.

PMID:
29419475
13.

Cytochrome b 5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b 5 /P450 reductase null (HBRN) mice.

Reed L, Mrizova I, Barta F, Indra R, Moserova M, Kopka K, Schmeiser HH, Wolf CR, Henderson CJ, Stiborova M, Phillips DH, Arlt VM.

Arch Toxicol. 2018 Apr;92(4):1625-1638. doi: 10.1007/s00204-018-2162-7. Epub 2018 Jan 24.

14.

68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer.

Sachpekidis C, Bäumer P, Kopka K, Hadaschik BA, Hohenfellner M, Kopp-Schneider A, Haberkorn U, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):904-912. doi: 10.1007/s00259-018-3936-0. Epub 2018 Jan 23.

PMID:
29362859
15.

[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty.

Giesel FL, Will L, Paddubny K, Kremer C, Rathke H, Radtke JP, Kopka K, Haufe S, Haberkorn U, Kratochwil C.

Clin Genitourin Cancer. 2018 Apr;16(2):111-113. doi: 10.1016/j.clgc.2017.11.008. Epub 2017 Dec 6. No abstract available.

16.

Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.

Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, Neels O, Reyneke F, Haberkon U, Kopka K, Sathekge M.

J Nucl Med. 2018 Jul;59(7):1076-1080. doi: 10.2967/jnumed.117.204669. Epub 2017 Dec 21.

PMID:
29269569
17.

Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients.

Will L, Giesel FL, Freitag MT, Berger AK, Mier W, Kopka K, Koerber SA, Rathke H, Kremer C, Kratochwil C, Kauczor HU, Haberkorn U, Weber TF.

Cancer Imaging. 2017 Dec 20;17(1):30. doi: 10.1186/s40644-017-0132-6.

18.

PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.

Baranski AC, Schäfer M, Bauder-Wüst U, Roscher M, Schmidt J, Stenau E, Simpfendörfer T, Teber D, Maier-Hein L, Hadaschik B, Haberkorn U, Eder M, Kopka K.

J Nucl Med. 2018 Apr;59(4):639-645. doi: 10.2967/jnumed.117.201293. Epub 2017 Nov 30.

PMID:
29191856
19.

Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.

Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F.

Theranostics. 2017 Sep 26;7(18):4359-4369. doi: 10.7150/thno.20586. eCollection 2017.

20.

Reply: PSMA Ligands for Imaging Prostate Cancer: Alternative Labeling by Complex Formation with Al18F2.

Giesel FL, Kopka K.

J Nucl Med. 2017 Dec;58(12):2041. doi: 10.2967/jnumed.117.198176. Epub 2017 Nov 9. No abstract available.

21.

Carbon ion radiotherapy: impact of tumor differentiation on local control in experimental prostate carcinomas.

Glowa C, Peschke P, Brons S, Neels OC, Kopka K, Debus J, Karger CP.

Radiat Oncol. 2017 Nov 9;12(1):174. doi: 10.1186/s13014-017-0914-9.

22.

Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy.

Paddubny K, Freitag MT, Kratochwil C, Koerber S, Radtke JP, Sakovich R, Kopka K, Giesel FL.

Clin Genitourin Cancer. 2018 Apr;16(2):103-105. doi: 10.1016/j.clgc.2017.09.014. Epub 2017 Oct 5. No abstract available.

23.

Comparison of human cytochrome P450 1A1-catalysed oxidation of benzo[a]pyrene in prokaryotic and eukaryotic expression systems.

Stiborová M, Indra R, Moserová M, Bořek-Dohalská L, Hodek P, Frei E, Kopka K, Schmeiser HH, Arlt VM.

Monatsh Chem. 2017;148(11):1959-1969. doi: 10.1007/s00706-017-2002-0. Epub 2017 Jul 10.

24.

Improved clinical workflow for simultaneous whole-body PET/MRI using high-resolution CAIPIRINHA-accelerated MR-based attenuation correction.

Freitag MT, Fenchel M, Bäumer P, Heußer T, Rank CM, Kachelrieß M, Paech D, Kopka K, Bickelhaupt S, Dimitrakopoulou-Strauss A, Maier-Hein K, Floca R, Ladd ME, Schlemmer HP, Maier F.

Eur J Radiol. 2017 Nov;96:12-20. doi: 10.1016/j.ejrad.2017.09.007. Epub 2017 Sep 13.

PMID:
29103469
25.

Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study.

Freitag MT, Kesch C, Cardinale J, Flechsig P, Floca R, Eiber M, Bonekamp D, Radtke JP, Kratochwil C, Kopka K, Hohenfellner M, Stenzinger A, Schlemmer HP, Haberkorn U, Giesel F.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):340-347. doi: 10.1007/s00259-017-3854-6. Epub 2017 Oct 16.

PMID:
29038888
26.

Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer.

Cardinale J, Martin R, Remde Y, Schäfer M, Hienzsch A, Hübner S, Zerges AM, Marx H, Hesse R, Weber K, Smits R, Hoepping A, Müller M, Neels OC, Kopka K.

Pharmaceuticals (Basel). 2017 Sep 27;10(4). pii: E77. doi: 10.3390/ph10040077.

27.

Identification of Ligands and Translation to Clinical Applications.

Haberkorn U, Mier W, Kopka K, Herold-Mende C, Altmann A, Babich J.

J Nucl Med. 2017 Sep;58(Suppl 2):27S-33S. doi: 10.2967/jnumed.116.186791. Review.

28.

Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers.

Kopka K, Benešová M, Bařinka C, Haberkorn U, Babich J.

J Nucl Med. 2017 Sep;58(Suppl 2):17S-26S. doi: 10.2967/jnumed.116.186775. Review.

29.

Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI.

Heußer T, Mann P, Rank CM, Schäfer M, Dimitrakopoulou-Strauss A, Schlemmer HP, Hadaschik BA, Kopka K, Bachert P, Kachelrieß M, Freitag MT.

PLoS One. 2017 Aug 17;12(8):e0183329. doi: 10.1371/journal.pone.0183329. eCollection 2017.

30.

Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq.

Rathke H, Giesel FL, Flechsig P, Kopka K, Mier W, Hohenfellner M, Haberkorn U, Kratochwil C.

J Nucl Med. 2018 Mar;59(3):459-465. doi: 10.2967/jnumed.117.194209. Epub 2017 Aug 10.

31.

Improving the Imaging Contrast of 68Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties.

Baranski AC, Schäfer M, Bauder-Wüst U, Wacker A, Schmidt J, Liolios C, Mier W, Haberkorn U, Eisenhut M, Kopka K, Eder M.

Bioconjug Chem. 2017 Sep 20;28(9):2485-2492. doi: 10.1021/acs.bioconjchem.7b00458. Epub 2017 Aug 24.

PMID:
28787147
32.

Erratum to: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1781. doi: 10.1007/s00259-017-3763-8. No abstract available.

PMID:
28656360
33.

68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.

Vinsensia M, Chyoke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, Rauscher I, Mier W, Schwaiger M, Haberkorn U, Mauer T, Kratochwil C, Eiber M, Giesel FL.

J Nucl Med. 2017 Dec;58(12):1949-1955. doi: 10.2967/jnumed.116.185033. Epub 2017 Jun 21.

34.

Syntheses of Radioiodinated Pyrimidine-2,4,6-Triones as Potential Agents for Non-Invasive Imaging of Matrix Metalloproteinases.

Breyholz HJ, Kopka K, Schäfers M, Wagner S.

Pharmaceuticals (Basel). 2017 May 30;10(2). pii: E49. doi: 10.3390/ph10020049.

35.

Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI.

Afshar-Oromieh A, Wolf M, Haberkorn U, Kachelrieß M, Gnirs R, Kopka K, Schlemmer HP, Freitag MT.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1636-1646. doi: 10.1007/s00259-017-3718-0. Epub 2017 May 15.

PMID:
28508120
36.

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268. doi: 10.1007/s00259-017-3711-7. Epub 2017 May 12. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Sep;44(10 ):1781.

37.

Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study.

Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, Holland-Letz T, Duensing S, Grabe N, Afshar-Oromieh A, Wieczorek K, Schäfer M, Neels OC, Cardinale J, Kratochwil C, Hohenfellner M, Kopka K, Haberkorn U, Hadaschik BA, Giesel FL.

J Nucl Med. 2017 Nov;58(11):1805-1810. doi: 10.2967/jnumed.116.189233. Epub 2017 May 4.

38.

68Ga or 18F for Prostate Cancer Imaging?

Kesch C, Kratochwil C, Mier W, Kopka K, Giesel FL.

J Nucl Med. 2017 May;58(5):687-688. doi: 10.2967/jnumed.117.190157. Epub 2017 Apr 13. No abstract available.

39.

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024. doi: 10.1007/s00259-017-3670-z.

PMID:
28283702
40.

Radiolabeled prostate-specific membrane antigen small-molecule inhibitors.

Will L, Sonni I, Kopka K, Kratochwil C, Giesel FL, Haberkorn U.

Q J Nucl Med Mol Imaging. 2017 Jun;61(2):168-180. doi: 10.23736/S1824-4785.17.02977-6. Epub 2017 Feb 17. Review.

41.

18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer.

Giesel FL, Kesch C, Yun M, Cardinale J, Haberkorn U, Kopka K, Kratochwil C, Hadaschik BA.

Clin Genitourin Cancer. 2017 Jun;15(3):e497-e499. doi: 10.1016/j.clgc.2016.12.029. Epub 2016 Dec 29. No abstract available.

42.

The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer.

Afshar-Oromieh A, Sattler LP, Mier W, Hadaschik BA, Debus J, Holland-Letz T, Kopka K, Haberkorn U.

J Nucl Med. 2017 May;58(5):750-755. doi: 10.2967/jnumed.116.183483. Epub 2017 Jan 6.

43.

[Significance of PSMA imaging in prostate cancer].

Gasch C, Düwel C, Kopka K, Kratochwil C, Vinsensia M, Eiber M, Maurer T, Haberkorn U, Hadaschik B, Giesel FL.

Urologe A. 2017 Jan;56(1):3-12. doi: 10.1007/s00120-016-0293-0. German.

PMID:
28005153
44.

Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI.

Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, Bonekamp D, Kopka K, Eder M, Heusser T, Kachelriess M, Wieczorek K, Sachpekidis C, Flechsig P, Giesel F, Hohenfellner M, Haberkorn U, Schlemmer HP, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2017 May;44(5):776-787. doi: 10.1007/s00259-016-3594-z. Epub 2016 Dec 17.

PMID:
27988802
45.

Radiolabeled Selective Matrix Metalloproteinase 13 (MMP-13) Inhibitors: (Radio)Syntheses and in Vitro and First in Vivo Evaluation.

Hugenberg V, Wagner S, Kopka K, Schäfers M, Schuit RC, Windhorst AD, Hermann S.

J Med Chem. 2017 Jan 12;60(1):307-321. doi: 10.1021/acs.jmedchem.6b01284. Epub 2016 Dec 16.

PMID:
27981835
46.

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.

Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688. doi: 10.1007/s00259-016-3573-4. Epub 2016 Nov 26.

47.

Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier.

Gerwien H, Hermann S, Zhang X, Korpos E, Song J, Kopka K, Faust A, Wenning C, Gross CC, Honold L, Melzer N, Opdenakker G, Wiendl H, Schäfers M, Sorokin L.

Sci Transl Med. 2016 Nov 9;8(364):364ra152.

PMID:
27831901
48.

Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging.

Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, Neels OC, Haberkorn U, Giesel FL, Kopka K.

J Nucl Med. 2017 Mar;58(3):425-431. doi: 10.2967/jnumed.116.181768. Epub 2016 Oct 27.

49.

68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer.

Sachpekidis C, Kopka K, Eder M, Hadaschik BA, Freitag MT, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A.

Clin Nucl Med. 2016 Nov;41(11):e473-e479.

50.

The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.

Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, Haberkorn U.

J Nucl Med. 2016 Oct;57(Suppl 3):79S-89S. Review.

Supplemental Content

Support Center